Back to Gefitinib

Gefitinib

Showing 3 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	median follow-up [months]⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	2	62.0	18.0	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	EGFR targeting TKI	Gefitinib	—	Missing	intra-cranial	brain	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	2	62.0	18.0	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	EGFR targeting TKI	Gefitinib	—	Missing	extra-cranial	lung	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Wang et al.	2014	Prospective	Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer	10.1097/COC.0b013e31826e071b	Missing	14	70.5	15.5	Lung cancer	any	N/A, EGFR targeting TKI	Gefitinib	—	Missing	extra-cranial	lung	—	Missing	45.0	60.0	Missing	3	5	Missing	Missing	Missing	Treatment-rel.	—	2	—	acute G3: 6 AEs, late G3: 2 AEs	acute G3: unknown pts, late G3: 2 pts	acute G3: skin rash/acne, stomatitis, esophagitis, diarrhea, pneumonitis, fatigue, late G3: radiation pneumonitis	acute G3: unknown, late G3: radiation pneumonitis